DK3658194T3 - Kombineret radiotracer og -terapeutika - Google Patents

Kombineret radiotracer og -terapeutika Download PDF

Info

Publication number
DK3658194T3
DK3658194T3 DK18743540.9T DK18743540T DK3658194T3 DK 3658194 T3 DK3658194 T3 DK 3658194T3 DK 18743540 T DK18743540 T DK 18743540T DK 3658194 T3 DK3658194 T3 DK 3658194T3
Authority
DK
Denmark
Prior art keywords
radiotracer
therapeutics
combined
combined radiotracer
Prior art date
Application number
DK18743540.9T
Other languages
Danish (da)
English (en)
Inventor
Hans-Jürgen Wester
Matthias Johannes Eiber
Alexander Josef Wurzer
Original Assignee
Univ Muenchen Tech
Technische Univ Muenchen Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Technische Univ Muenchen Klinikum Rechts Der Isar filed Critical Univ Muenchen Tech
Application granted granted Critical
Publication of DK3658194T3 publication Critical patent/DK3658194T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
DK18743540.9T 2017-07-28 2018-07-30 Kombineret radiotracer og -terapeutika DK3658194T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (1)

Publication Number Publication Date
DK3658194T3 true DK3658194T3 (da) 2025-02-17

Family

ID=59501286

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18743540.9T DK3658194T3 (da) 2017-07-28 2018-07-30 Kombineret radiotracer og -terapeutika

Country Status (20)

Country Link
US (4) US11413360B2 (enExample)
EP (3) EP4424378A3 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR20240027896A (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL272291B2 (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
BR112021012110A2 (pt) * 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
KR20230066382A (ko) 2020-09-03 2023-05-15 큐리엄 유에스 엘엘씨 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
IL305134A (en) * 2021-02-15 2023-10-01 Technische Universit?T M?Nchen Dual mode radio and medical tracker
CA3215723A1 (en) * 2021-04-02 2022-10-06 Advanced Accelerator Applications Diagnostic methods of prostate cancer
JP2024517971A (ja) * 2021-05-14 2024-04-23 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
US20250313579A1 (en) * 2021-08-05 2025-10-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
CA3264385A1 (en) * 2022-09-20 2024-03-28 Universität Augsburg NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
IL319722A (en) 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7384394A (en) * 1993-06-30 1995-01-24 Akzo Nobel N.V. Chelating compounds
EP1420831A1 (en) * 2001-07-27 2004-05-26 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
EP3303349B1 (en) * 2015-05-26 2022-07-06 The Regents of the University of California Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
DK3723815T3 (da) * 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
WO2020157177A1 (en) 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic

Also Published As

Publication number Publication date
MX2020000352A (es) 2020-08-17
US20260021211A1 (en) 2026-01-22
EA202090370A1 (ru) 2020-05-25
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
ES3011272T3 (en) 2025-04-07
FI3658194T3 (fi) 2025-02-28
KR20240027896A (ko) 2024-03-04
JP2020528461A (ja) 2020-09-24
IL272291B1 (en) 2025-02-01
WO2019020831A1 (en) 2019-01-31
AU2018308699A1 (en) 2020-01-23
AU2024200440A1 (en) 2024-02-08
SG11202000725WA (en) 2020-02-27
US20220370649A1 (en) 2022-11-24
JP2022101601A (ja) 2022-07-06
EP3658194B1 (en) 2024-11-27
PT3658194T (pt) 2025-02-13
US12390540B2 (en) 2025-08-19
IL272291B2 (en) 2025-06-01
EP3658194A1 (en) 2020-06-03
CA3071315A1 (en) 2019-01-31
KR102752620B1 (ko) 2025-01-10
NZ760537A (en) 2026-01-30
IL318092A (en) 2025-02-01
AU2024200440B2 (en) 2025-04-24
PL3658194T3 (pl) 2025-09-15
MX2023007914A (es) 2023-07-13
CN111132700B (zh) 2022-12-13
US20200197545A1 (en) 2020-06-25
US20250121102A1 (en) 2025-04-17
EP4424378A2 (en) 2024-09-04
HUE070098T2 (hu) 2025-05-28
EP4000640A1 (en) 2022-05-25
ZA202000467B (en) 2022-06-29
AU2018308699B2 (en) 2023-11-30
CN111132700A (zh) 2020-05-08
US11413360B2 (en) 2022-08-16
BR112020001785A2 (pt) 2020-09-29
IL272291A (en) 2020-03-31
JP7059372B2 (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
IL285286A (en) Transposase polypeptides and uses thereof
IL293377A (en) Hsd17b13 variants and uses thereof
EP3722358A4 (en) COMPOSITION
HRP20260151T1 (hr) Modificirani polipeptidi i njihova uporaba
DK3697376T3 (da) Sammensætning
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
KR20180084891A (ko) 구조 조성물 및 방법
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
PL3603620T3 (pl) Kompozycja liposomowa i kompozycja farmaceutyczna
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
EP3534910A4 (en) THERAPEUTIC METHODS AND AGENTS
EP3417845A4 (en) ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION
GB201707079D0 (en) Novel compounds and therapeutics uses thereof
MA49905A (fr) Polyesteramines et polyesterquats
IL264445A (en) Compounds and compositions and uses thereof
EP3675653C0 (fr) Composition antimycotoxine
EP3298014A4 (en) S1pr2 antagonists and uses therefor
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser
EP3305309A4 (en) ANTICARIOGENIC AGENT AND ANTICARIAC COMPOSITION
ES1209313Y (es) Composicion liofilizada
EP3565570C0 (en) COMPOSITION